Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Notes Payables (2016 - 2022)

Historic Notes Payables for Pharma (IGC) over the last 13 years, with Q2 2022 value amounting to $3000.0.

  • Pharma's Notes Payables changed 0.0% to $3000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $3000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $3000.0 for FY2022, which is 9901.32% down from last year.
  • Pharma's Notes Payables amounted to $3000.0 in Q2 2022, which was down 0.0% from $3000.0 recorded in Q1 2022.
  • Over the past 5 years, Pharma's Notes Payables peaked at $1.8 million during Q1 2018, and registered a low of $3000.0 during Q2 2021.
  • Its 5-year average for Notes Payables is $401062.5, with a median of $50000.0 in 2019.
  • As far as peak fluctuations go, Pharma's Notes Payables surged by 50800.0% in 2021, and later plummeted by 9901.32% in 2022.
  • Quarter analysis of 5 years shows Pharma's Notes Payables stood at $1.8 million in 2018, then crashed by 97.22% to $50000.0 in 2019, then skyrocketed by 404.0% to $252000.0 in 2020, then tumbled by 98.81% to $3000.0 in 2021, then changed by 0.0% to $3000.0 in 2022.
  • Its Notes Payables was $3000.0 in Q2 2022, compared to $3000.0 in Q1 2022 and $3000.0 in Q4 2021.